论文部分内容阅读
临床上应用白介素-2(IL-2)或IL-2/LAK细胞治疗病毒性肝炎已取得一定的疗效,而IL-2的给药方式大多为大剂量静脉输注,治疗时间较长,常产生一些毒副作用,且治疗费用昂贵。我们采用低剂量rIL-2直接注射到慢性乙型肝炎患者淋巴结(iLN)中,并与肌内注射(im)和静脉内滴注(iv)比较,观察3种给药方式对患者的T细胞亚群、体外激活后增殖能力和杀伤活性的影响,以期探索一种简便、有效和经济的给药方式。 1 材料和方法 1.1 材料根据1990年上海全国病毒性肝炎会议修订的诊断标准,慢性乙型肝炎共68例;其中慢迁肝18例,慢活肝50例;年龄18岁～50岁,男39例,女29例,血清HBsAg,HBcAb,HBeAg及HBV-DNA均阳性。rIL-2(南京军区医学研究所);
Clinical application of interleukin-2 (IL-2) or IL-2 / LAK cells in the treatment of viral hepatitis has achieved some efficacy, while the IL-2 administration is mostly high-dose intravenous infusion, treatment for a long time, often Produce some side effects, and the cost of treatment is expensive. We injected low-dose rIL-2 directly into iLN patients and compared them with intramuscular (im) and intravenous drip (iv). The effects of three administration methods on T cells of patients Subpopulation, proliferative ability and cytotoxic activity after in vitro activation in order to explore a simple, effective and economical way of administration. Materials and Methods 1.1 Materials According to the diagnostic criteria revised by Shanghai National Viral Hepatitis Conference in 1990, a total of 68 cases of chronic hepatitis B were observed. Among them, 18 cases were slow-moving liver and 50 cases were slow-living liver. Aged 18 to 50 years old, male 39 Cases, female 29 cases, serum HBsAg, HBcAb, HBeAg and HBV-DNA were positive. rIL-2 (Nanjing Military Medical Institute);